CD23 expression in follicular lymphoma: Clinicopathologic correlations

American Journal of Clinical Pathology

Volumn 135, Issue 1, 2011, Pages 46-53

  Olteanu, Horatiu ^a   Fenske, Timothy S ^a   Harrington, Alexandra M ^a   Szabo, Aniko ^a   He, Peng ^a   Kroft, Steven H ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

CD23; Flow cytometry; Follicular lymphoma; Immunophenotype

Indexed keywords

CD23 ANTIGEN;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INGUINAL LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LYMPH NODES; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, IGE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; WISCONSIN;

EID: 79251510889     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP27YWLIQRAJPW     Document Type: Article

References (42)

1. Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2007:216-225.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
3. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993;20(5 suppl 5):75-88.
4. Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23:5019-5026.
5. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447-8452.
6. Solal-Celigny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood. 2004;104:1258-1265.
7. Perea G, Altes A, Montoto S, et al. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol. 2005;16:1508-1513.
8. Arcaini L, Colombo N, Passamonti F, et al. Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leuk Res. 2006;30:277-282.
9. Buske C, Hoster E, Dreyling M, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504-1508.
10. Federico M, Bellei M, Marcheselli L, et al. Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol. 2009;27:4555-4562.
11. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159-2169.
12. Harris NL, Swerdlow SH, Jaffe ES, et al. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:220-226.
13. Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood. 2002;99:3806-3812. (Pubitemid 34534555)
14. Xu Y, McKenna RW, Kroft SH. Assessment of CD10 in the diagnosis of small B-cell lymphomas: a multiparameter flow cytometric study. Am J Clin Pathol. 2002;117:291-300. (Pubitemid 34823671)
15. Ray S, Craig FE, Swerdlow SH. Abnormal patterns of antigenic expression in follicular lymphoma: a flow cytometric study. Am J Clin Pathol. 2005;124:576-583. (Pubitemid 41395639)
16. Garcia DP, Rooney MT, Ahmad E, et al. Diagnostic usefulness of CD23 and FMC-7 antigen expression patterns in B-cell lymphoma classification. Am J Clin Pathol. 2001;115:258-265. (Pubitemid 32150685)
17. Xu Y, McKenna RW, Asplund SL, et al. Comparison of immunophenotypes of small B-cell neoplasms in primary lymph node and concurrent blood or marrow samples. Am J Clin Pathol. 2002;118:758-764. (Pubitemid 37046321)
18. Ahmad E, Garcia D, Davis BH. Clinical utility of CD23 and FMC7 antigen coexistent expression in B-cell lymphoproliferative disorder subclassification. Cytometry. 2002;50:1-7.
19. Gujral S, Polampalli SN, Badrinath Y, et al. Immunophenotyping of mature B-cell non Hodgkin lymphoma involving bone marrow and peripheral blood: critical analysis and insights gained at a tertiary care cancer hospital. Leuk Lymphoma. 2009;50:1290-1300.
20. Bonnefoy JY, Lecoanet-Henchoz S, Gauchat JF, et al. Structure and functions of CD23. Int Rev Immunol. 1997;16:113-128.
21. Kijimoto-Ochiai S. CD23 (the low-affinity IgE receptor) as a C-type lectin: a multidomain and multifunctional molecule. Cell Mol Life Sci. 2002;59:648-664.
22. Liu YJ, Cairns JA, Holder MJ, et al. Recombinant 25-kDa CD23 and interleukin 1 alpha promote the survival of germinal center B cells: evidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur J Immunol. 1991;21:1107-1114.
23. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640-1645. (Pubitemid 24323778)
24. Kelemen K, Peterson LC, Helenowski I, et al. CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease. Am J Clin Pathol. 2008;130:166-177.
25. Dadmarz R, Cawley JC. Heterogeneity of CLL: high CD23 antigen and alpha IFN receptor expression are features of favourable disease and of cell activation. Br J Haematol. 1988;68:279-282.
26. Linderoth J, Jerkeman M, Cavallin-Stahl E, et al. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res. 2003;9:722-728. (Pubitemid 36182606)
27. Walters M, Olteanu H, Van Tuinen P, et al. CD23 expression in plasma cell myeloma is specific for abnormalities of chromosome 11, and is associated with primary plasma cell leukaemia in this cytogenetic sub-group [letter]. Br J Haematol. 2010;149:292-293.
28. Thorns C, Kalies K, Fischer U, et al. Significant high expression of CD23 in follicular lymphoma of the inguinal region. Histopathology. 2007;50:716-719. (Pubitemid 46683931)
29. Katzenberger T, Kalla J, Leich E, et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood. 2009;113:1053-1061.
30. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
31. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
32. Naresh KN. Inability to validate an association between CD23 expression and site or grade of follicular lymphoma [letter]. Histopathology. 2008;52:241.
33. Sacchi S, Pozzi S, Marcheselli L, et al. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer. 2007;109:2077-2082.
34. Pathan NI, Chu P, Hariharan K, et al. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood. 2008;111:1594-1602.
35. Byrd JC, O'Brien S, Flinn IW, et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007;13(15 pt 1):4448-4455. (Pubitemid 47219713)
36. Mayer RJ, Flamberg PL, Katchur SR, et al. CD23 shedding: requirements for substrate recognition and inhibition by dipeptide hydroxamic acids. Inflamm Res. 2002;51:85-90.
37. Geisler CH, Larsen JK, Hansen NE, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood. 1991;78:1795-1802.
38. Sarfati M, Bron D, Lagneaux L, et al. Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. Blood. 1988;71:94-98.
39. Hubmann R, Düchler M, Schnabl S, et al. NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol. 2010;148:868-878. doi:10.1111/j.1365-2141.2009.08024.x.
40. Rosati E, Sabatini R, Rampino G, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood. 2009;113:856-865.
41. Lee SY, Kumano K, Nakazaki K, et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci. 2009;100:920-926.
42. Troen G, Wlodarska I, Warsame A, et al. NOTCH2 mutations in marginal zone lymphoma. Haematologica. 2008;93:1107-1109.